Metvix (Methyl Aminolevulinate)

Methyl aminolevulinate is converted inside skin cells to protoporphyrin IX, a photosensitizer. When the treated area is illuminated with red light, the compound generates reactive oxygen species that selectively destroy abnormal keratinocytes while sparing normal tissue.

The prescribed amount of Metvix is determined by the treating physician based on lesion size, number, and location. The healthcare professional will instruct the patient on the exact quantity to apply and the timing of light activation.

The safety of Metvix in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Metvix product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metvix offers a photodynamic approach that selectively targets abnormal cells, whereas alternative options such as topical 5‑fluorouracil, imiquimod or cryotherapy rely on cytotoxic or destructive mechanisms. Photodynamic therapy can provide precise lesion clearance with a lower risk of scarring, but requires specialized light equipment.

Store Metvix at room temperature, below 25 °C, in the original packaging. Keep the container tightly closed, protect it from light and moisture, and avoid freezing to maintain product stability.

The cream is applied topically to the cleaned lesion area by a qualified professional. After a defined incubation period, the treated skin is exposed to red light of a specific wavelength to activate the photosensitizer. Post‑treatment care instructions are provided by the clinician.

Serious risks include severe photosensitivity reactions, infection of the treated site, persistent ulceration, and rare allergic contact dermatitis. Patients should be monitored closely for these events, and any signs of severe reaction should prompt immediate medical evaluation.

Metvix should not be used in individuals with known hypersensitivity to methyl aminolevulinate or any cream excipients, patients with porphyria, or those who cannot avoid light exposure after treatment. Contraindications are determined by the prescribing clinician.